A Study to Assess the Role of Biomarkers in Risk Stratification in Adults with Congenital Heart Disease


About this study

The purporse of this study is to determine if biomarker assay obtained at baseline can predict future risk of cardiovascular adverse events, and to  determine if temporal changes in biomarker levels can provide a better risk prediction compared to biomarker assay obtained at baseline.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients (age ≥ 18 years)
  • Adult patients with diagnosis of Congenital Heart Disease (i.e., Tetralogy of Fallot (TOF), Pulmonary Atresia, Coarctation of Aorta, etc.).

Exclusion Criteria: 

  • Patients without research authorization.

Eligibility last updated 11/10/21. Questions regarding updates should be directed to the study team contact.





Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alexander Egbe, M.B.B.S., M.P.H.

Open for enrollment

Contact information:

Adult Congenital Research Program

(507) 293-2565


More information


Publications are currently not available